Barclays raised the firm’s price target on ZimVie to $16 from $13 and keeps an Underweight rating on the shares. The analyst says that while ZimVie reacted positively to management’s planned divestiture of its spine business announced in December, the company’s continuing operations are now concentrated in the “sluggish market” for dental implants.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZIMV: